NEW YORK (GenomeWeb News) – Abbott reported today that its molecular diagnostics sales grew 4 percent year over year for its fourth quarter ended Dec. 31, 2012.

The diagnostics, medical devices, and pharmaceuticals giant reported molecular diagnostics sales of $131 million for the quarter, up from $126 million for the fourth quarter of 2011. Its core laboratory diagnostics revenues for the quarter were also up 4 percent to $908 million, while its point-of-care diagnostics sales climbed 15 percent to $90 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.